FedEx (FDX) Stock Dips While Market Gains: Key Facts
FedEx (FDX) closed at $217.89 in the latest trading session, marking a -0.1% move from the prior day. This move lagged the S&P 500's daily gain of 0.41%. Meanwhile, the Dow experienced a rise of 0.08%, and the technology-dominated Nasdaq saw an increase of 0.67%.
Coming into today, shares of the package delivery company had lost 0.74% in the past month. In that same time, the Transportation sector gained 10.25%, while the S&P 500 gained 6.13%.
Analysts and investors alike will be keeping a close eye on the performance of FedEx in its upcoming earnings disclosure. The company's earnings report is set to go public on June 24, 2025. It is anticipated that the company will report an EPS of $5.98, marking a 10.54% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $21.75 billion, showing a 1.62% drop compared to the year-ago quarter.
Investors might also notice recent changes to analyst estimates for FedEx. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.23% lower. As of now, FedEx holds a Zacks Rank of #4 (Sell).
In terms of valuation, FedEx is currently trading at a Forward P/E ratio of 12.01. This indicates a discount in contrast to its industry's Forward P/E of 13.77.
Investors should also note that FDX has a PEG ratio of 1.13 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Transportation - Air Freight and Cargo industry held an average PEG ratio of 1.71.
The Transportation - Air Freight and Cargo industry is part of the Transportation sector. With its current Zacks Industry Rank of 190, this industry ranks in the bottom 24% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
FedEx Corporation (FDX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 minutes ago
- Yahoo
Meridianbet Seals Sponsorship Deal with Aquatic Sports Association of Malta (ASA)
Two-year agreement expands Meridianbet and Golden Matrix's (GMGI) sports sponsorship portfolio across regulated European markets Aquatic Sports Association of Malta VALLETTA, Malta, June 04, 2025 (GLOBE NEWSWIRE) -- Meridianbet, the sports betting and iGaming division of Golden Matrix Group Inc. (NASDAQ: GMGI), a leading developer and licensor of B2B and B2C gaming platforms, today announced the signing of a two-year exclusive sponsorship agreement with the Aquatic Sports Association of Malta (ASA), the official governing body for water polo, swimming, and artistic swimming in Malta. Under the terms of the agreement, Meridianbet becomes the exclusive betting partner of ASA, gaining integrated brand exposure across ASA events, digital platforms, and physical venues. The sponsorship includes the launch of the branded national cup competition - Meridianbet Super Cup, as well as LED road signage, scoreboard branding, and apparel sponsorships across Malta's aquatic sports federations. 'Water polo and aquatic sports are a vital part of Malta's sporting culture,' said Stefan Pavlovic, Malta territory director at Meridianbet. 'This partnership reflects our continued commitment to supporting national sports ecosystems, building long-term brand visibility in regulated markets, and delivering value to fans, players, local institutions and shareholders.' The ASA partnership builds on Meridianbet's growing sponsorship portfolio across 25+ international jurisdictions, where it supports sports ranging from football, basketball and MMA to eSports and grassroots competitions. This announcement also aligns with Meridianbet's broader ESG strategy. In 2024 alone, the company conducted 293 community engagement initiatives, reaching over 18,000 direct and indirect beneficiaries through education, healthcare, sports, and advocacy programs. Key Highlights of the Deal: Meridianbet named exclusive betting partner of Malta's ASA (governing body for water polo, swimming, artistic swimming) Launch of the Meridianbet Super Cup Brand exposure via LED ads, digital platforms, and team apparel To learn more about Meridianbet's community impact programs, visit About Meridianbet Founded in 2001, Meridianbet Group is a well-established online sports betting and gaming group, licensed and currently operating in 18 jurisdictions across Europe, Africa, and South America. The Meridianbet Group's successful business model utilizes proprietary technology and scalable systems, allowing it to operate in multiple countries and currencies with an omni-channel approach to markets, including retail, desktop online, and mobile. The Company is part of the Golden Matrix Group (Nasdaq: GMGI). For more information, visit IR Presentation - YouTube - Twitter - Email: ir@ A photo accompanying this announcement is available at
Yahoo
15 minutes ago
- Yahoo
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company's first-in-class nucleotide-binding domain 1 (NBD1) stabilizers, in healthy volunteers. One hundred subjects were dosed in the SION-719 trial, and 110 subjects were dosed in the SION-451 trial. Data Highlights Both NBD1 stabilizers were generally well tolerated and achieved pharmacokinetic (PK) concentration targets established using Sionna's preclinical cystic fibrosis (CF) human bronchial epithelial (CFHBE) data reinforce the potential of both NBD1 stabilizers to provide clinically meaningful benefit for CF patients, including the potential for wild-type CFTR function, either as an add-on to standard of care (SOC), or in a proprietary dual combination with complementary modulators. Both compounds were generally well tolerated in the Phase 1 trials. There were no serious adverse events, treatment-emergent adverse events (TEAEs) that led to discontinuation of the drug, or dose-limiting TEAEs observed. Most TEAEs were mild to moderate. One Grade 1 TEAE related to liver function tests (LFTs) was observed in a SION-451-treated subject who tested positive for influenza; no TEAEs related to LFTs were observed in the other cohorts of SION-451. There were no TEAEs related to LFTs in SION-719-treated subjects. The data from Part C of each trial support the use of a tablet formulation in future studies and indicate that both compounds can be dosed in a fed or fasted state. SION-719 and SION-451 achieved the desired target PK concentrations at multiple doses twice daily. Both stabilizers met exposure thresholds that can provide clinically meaningful benefit if administered as an add-on to SOC or in a proprietary dual combination with complementary modulators. Next Steps For SION-719: Sionna is progressing SION-719 into a Phase 2a POC trial evaluating the compound as an add-on to SOC in CF patients. Sionna is on track to initiate this trial in the second half of 2025, with topline data anticipated in mid-2026. The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for SION-719. The first subject has been dosed in a midazolam drug-drug interaction (DDI) study to confirm that SION-719 can be dosed in combination with the SOC according to its label. The study will be completed before the Phase 2a trial is initiated. Next Steps For SION-451: Sionna plans to initiate a Phase 1 healthy volunteer dual combination trial evaluating SION-451 combined with SION-2222 (galicaftor) and SION-109. The trial will assess the safety, tolerability, and PK of varying doses of the dual combinations. It will inform the selection of a dual combination for a Phase 2b trial in CF patients. Sionna is on track to initiate the healthy volunteer trial in the second half of 2025, with topline data expected in mid-2026. In February, Sionna Therapeutics closed its upsized initial public offering of 12.18 million shares at $18.00 per share, with approximately $219.2 million in gross proceeds. Price Action: SION stock is trading higher by 6.80% to $15.47 at last check Wednesday. Read Next:Photo by Gorodenkoff via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data


CNBC
23 minutes ago
- CNBC
The biggest risk to valuations is what happens to 10-year rates, says Barclays' Venu Krishna
Venu Krishna, Barclays head of U.S. Equity Strategy, joins 'The Exchange' to discuss Barclays lifting it S&P target to 6,050.